TriangleNCT01866293 · OUTCOME
Time to Progression (TTP)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- 1 year
Analysis population: 9 participants are evaluable. 2 participants never started treatment.
Groups in this outcome
Cabozantinib (XL184)
Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
| Group | Source count |
|---|---|
| Cabozantinib (XL184) | 11 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cabozantinib (XL184) | 57 | Not reported | 28 | 85 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 28
- upper Limit
- 85
- value
- 57
- denoms
- counts
- group Id
- OG000
- value
- 11
- units
- Participants
- dispersion Type
- Full Range
- groups
- description
- Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
- id
- OG000
- title
- Cabozantinib (XL184)
- param Type
- MEDIAN
- population Description
- 9 participants are evaluable. 2 participants never started treatment.
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Time to Progression (TTP)
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice